"Plus Therapeutics (PSTV) recently reported a second-quarter loss that missed revenue estimates, although it has turned profitable and is preparing to launch a new cancer detection tool. The company has received an extension to meet Nasdaq listing requirements, but ongoing financial challenges and market performance may pose risks to its stability, reflected in a low sentiment score of 0.25."